CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 65 enrolled
Drug / intervention
EMST +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02927691
NCT02927691Phase 2Completed

Novel Management of Airway Protection in Parkinson's Disease: A Clinical Trial

Teachers College, Columbia University·interventional·Posted Oct 7, 2016·Updated Dec 22, 2023

In Brief

A Phase 2 clinical trial evaluating EMST and smTAP for Parkinson's Disease and 2 related conditions. Completed, enrolled 65 participants across 1 site.

Detailed Summary

Currently, there are no efficacious behavioral treatment approaches to address uncompensated aspiration, or aspiration without appropriate cough response, in Parkinson's disease (PD). This is of particular public health concern given that aspiration pneumonia is the leading cause of death in persons with PD. The overarching aim of the proposed study is to determine the efficacy of two distinct intensive rehabilitation paradigms, expiratory muscle strength training (EMST) and sensorimotor treatment for airway protection (smTAP), on airway protective clinical outcomes in persons with PD and dysphagia. The investigators anticipate the results will lead to reductions in the risks associated with airway protective deficits.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 7, 2016
Enrollment StartSep 1, 2016
Primary CompletionJun 1, 2021
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 9.7 years ago

Interventions

EMSTdevice

smTAPbehavioral